Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial

FY 2014-15

Summary
In the proposed randomized controlled trial (RCT), we seek to address the efficacy of evidence-based Interpersonal Psychotherapy (IPT) for the treatment of Major Depressive Disorder (MDD) using adjunctive intranasal oxytocin, which is a novel therapeutic. Intranasal oxytocin inhibits the release of stress hormones, in addition to increasing interpersonal trust, attachment security, openness, and suggestibility, all of which increase readiness for psychotherapy and improve the patient's alliance with the therapist. In short, adjunctive intranasal oxytocin demonstrates the capacity to improve a number of critical elements that are documented to enhance the efficacy of IPT, which already boasts a substantial evidence base for the treatment of MDD. The sample will include 32 patients suffering from MDD between the ages of 18 and 50. All potential patients will be assessed using structured diagnostic interviews as well as clinician and patient rated psychiatric symptom inventories prior to therapy. Patients that meet eligibility criteria following the first assessment will be randomized in blocks using a 1:1 ratio for treatment (oxytocin, 24IU) and control (placebo) conditions. Psychotherapy will consist of 16 one-hour psychotherapy sessions that will be scheduled one week apart, and each session will adhere to guidelines on administering IPT to depressed populations. Clinicians will be graduate students in clinical psychology with level A certification in IPT. We predict that IPT will be effective in remitting the diagnostic status of MDD in both oxytocin and placebo patient groups following intervention, as well as 6 months thereafter. Oxytocin is expected to show an advantage over placebo in improving all key outcome measures.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331277
Name
Kalogeropoulos Christopher
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adjunct; Interpersonal Psychotherapy; Intranasal Oxytocin; Major Depressive Disorder (Mdd); Treatment Outcome
Abstract
In the proposed randomized controlled trial (RCT), we seek to address the efficacy of evidence-based Interpersonal Psychotherapy (IPT) for the treatment of Major Depressive Disorder (MDD) using adjunctive intranasal oxytocin, which is a novel therapeutic. Intranasal oxytocin inhibits the release of stress hormones, in addition to increasing interpersonal trust, attachment security, openness, and suggestibility, all of which increase readiness for psychotherapy and improve the patient's alliance with the therapist. In short, adjunctive intranasal oxytocin demonstrates the capacity to improve a number of critical elements that are documented to enhance the efficacy of IPT, which already boasts a substantial evidence base for the treatment of MDD. The sample will include 32 patients suffering from MDD between the ages of 18 and 50. All potential patients will be assessed using structured diagnostic interviews as well as clinician and patient rated psychiatric symptom inventories prior to therapy. Patients that meet eligibility criteria following the first assessment will be randomized in blocks using a 1:1 ratio for treatment (oxytocin, 24IU) and control (placebo) conditions. Psychotherapy will consist of 16 one-hour psychotherapy sessions that will be scheduled one week apart, and each session will adhere to guidelines on administering IPT to depressed populations. Clinicians will be graduate students in clinical psychology with level A certification in IPT. We predict that IPT will be effective in remitting the diagnostic status of MDD in both oxytocin and placebo patient groups following intervention, as well as 6 months thereafter. Oxytocin is expected to show an advantage over placebo in improving all key outcome measures.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kalogeropoulos, Christopher
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~